Interleukin-1 family cytokines and their regulatory proteins in normal pregnancy and pre-eclampsia

Clinical and Experimental Immunology

Volumn 181, Issue 3, 2015, Pages 480-490

  Southcombe, J H ^a   Redman, C W G ^a   Sargent, I L ^a   Granne, I ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

Cytokines; IL 1 superfamily; Pre eclampsia; Pregnancy

Indexed keywords

BETA ACTIN; CYTOKINE; INTERLEUKIN 1; INTERLEUKIN 1 RECEPTOR ACCESSORY PROTEIN; INTERLEUKIN 36 ALPHA; INTERLEUKIN 36 BETA; INTERLEUKIN 36 GAMMA; INTERLEUKIN 37; INTERLEUKIN 38; INTERLEUKIN 8 BINDING PROTEIN; REGULATOR PROTEIN; UNCLASSIFIED DRUG; IL-38 PROTEIN, HUMAN; IL37 PROTEIN, HUMAN; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN DERIVATIVE; INTERLEUKIN-18 BINDING PROTEIN; SIGNAL PEPTIDE;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE RESPONSE; DIASTOLIC BLOOD PRESSURE; ENZYME LINKED IMMUNOSORBENT ASSAY; EXOSOME; FEMALE; HUMAN; HUMAN TISSUE; MATERNAL PLASMA; PLACENTA; PLACENTA PERFUSION; PREECLAMPSIA; PREGNANCY; PREGNANT WOMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; SYNCYTIOTROPHOBLAST; TROPHOBLAST; BLOOD; CELL HYPOXIA; CHORIOCARCINOMA; IMMUNOBLOTTING; METABOLISM; PATHOLOGY; TUMOR CELL LINE; U937 CELL LINE;

ADULT; CELL HYPOXIA; CELL LINE, TUMOR; CHORIOCARCINOMA; CYTOKINES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; IMMUNOBLOTTING; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; INTERLEUKIN 1 RECEPTOR ANTAGONIST PROTEIN; INTERLEUKIN-1; INTERLEUKIN-1 RECEPTOR ACCESSORY PROTEIN; INTERLEUKINS; PLACENTA; PRE-ECLAMPSIA; PREGNANCY; U937 CELLS;

EID: 84939137717     PISSN: 00099104     EISSN: 13652249     Source Type: Journal    
DOI: 10.1111/cei.12608     Document Type: Article

References (60)

1. Steegers EA, von Dadelszen P, Duvekot JJ, Pijnenborg R. Pre-eclampsia. Lancet 2010; 376:631-44.
2. Redman CW, Sargent IL. Placental stress and pre-eclampsia: a revised view. Placenta 2009; 30(Suppl A): S38-42.
3. Redman CW. Preeclampsia: a multi-stress disorder. Rev Med Interne 2011; 32(Suppl 1):S41-4.
4. Hwang I. Cell-cell communication via extracellular membrane vesicles and its role in the immune response. Mol Cell 2013; 36:105-11.
5. Redman CW, Sacks GP, Sargent IL. Preeclampsia: an excessive maternal inflammatory response to pregnancy. Am J Obstet Gynecol 1999; 180:499-506.
6. Santner-Nanan B, Peek MJ, Khanam R et al. Systemic increase in the ratio between Foxp3+ and IL-17-producing CD4+ T cells in healthy pregnancy but not in preeclampsia. J Immunol 2009; 183:7023-30.
7. Maynard SE, Min JY, Merchan J et al. Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. J Clin Invest 2003; 111:649-58.
8. Taylor RN, Grimwood J, Taylor RS, McMaster MT, Fisher SJ, North RA. Longitudinal serum concentrations of placental growth factor: evidence for abnormal placental angiogenesis in pathologic pregnancies. Am J Obstet Gynecol 2003; 188:177-82.
9. Challis JR, Lockwood CJ, Myatt L, Norman JE, Strauss JF III, Petraglia F. Inflammation and pregnancy. Reprod Sci 2009; 16:206-15.
10. Benyo DF, Smarason A, Redman CW, Sims C, Conrad KP. Expression of inflammatory cytokines in placentas from women with preeclampsia. J Clin Endocrinol Metab 2001; 86:2505-12.
11. Conrad KP, Miles TM, Benyo DF. Circulating levels of immunoreactive cytokines in women with preeclampsia. Am J Reprod Immunol 1998; 40:102-11.
12. Kocyigit Y, Atamer Y, Atamer A, Tuzcu A, Akkus Z. Changes in serum levels of leptin, cytokines and lipoprotein in pre-eclamptic and normotensive pregnant women. Gynecol Endocrinol 2004; 19:267-73.
13. Kalinderis M, Papanikolaou A, Kalinderi K et al. Elevated serum levels of interleukin-6, interleukin-1beta and human chorionic gonadotropin in pre-eclampsia. Am J Reprod Immunol 2011; 66:468-75.
14. Akira S, Takeda K. Toll-like receptor signalling. Nat Rev Immunol 2004; 4:499-511.
15. Polentarutti N, Rol GP, Muzio M et al. Unique pattern of expression and inhibition of IL-1 signaling by the IL-1 receptor family member TIR8/SIGIRR. Eur Cytokine Netw 2003; 14:211-8.
16. Wald D, Qin J, Zhao Z et al. SIGIRR, a negative regulator of Toll-like receptor-interleukin 1 receptor signaling. Nat Immunol 2003; 4:920-7.
17. Dinarello CA. Immunological and inflammatory functions of the interleukin-1 family. Annu Rev Immunol 2009; 27:519-50.
18. Boraschi D, Lucchesi D, Hainzl S et al. IL-37: a new anti-inflammatory cytokine of the IL-1 family. Eur Cytokine Netw 2011; 22:127-47.
19. Smith DE, Hanna R, Della F et al. The soluble form of IL-1 receptor accessory protein enhances the ability of soluble type II IL-1 receptor to inhibit IL-1 action. Immunity 2003; 18:87-96.
20. Greer IA, Lyall F, Perera T, Boswell F, Macara LM. Increased concentrations of cytokines interleukin-6 and interleukin-1 receptor antagonist in plasma of women with preeclampsia: a mechanism for endothelial dysfunction? Obstet Gynecol 1994; 84:937-40.
21. Kimya Y, Akdis C, Cengiz C et al. Plasma interleukin-1alpha, interleukin-1beta and interleukin-1 receptor antagonist levels in pre-eclampsia. Eur J Obstet Gynecol Reprod Biol 1997; 73:17-21.
22. Szarka A, Rigo J Jr, Lazar L, Beko G, Molvarec A. Circulating cytokines, chemokines and adhesion molecules in normal pregnancy and preeclampsia determined by multiplex suspension array. BMC Immunol 2010; 11:59.
23. Amash A, Holcberg G, Sapir O, Huleihel M. Placental secretion of interleukin-1 and interleukin-1 receptor antagonist in preeclampsia: effect of magnesium sulfate. J Interferon Cytokine Res 2012; 32:432-41.
24. Miller AM. Role of IL-33 in inflammation and disease. J Inflamm (Lond) 2011; 8:22.
25. Granne I, Southcombe JH, Snider JV et al. ST2 and IL-33 in pregnancy and pre-eclampsia. PLOS ONE 2011; 6:e24463.
26. Fock V, Mairhofer M, Otti GR et al. Macrophage-derived IL-33 is a critical factor for placental growth. J Immunol 2013; 191:3734-43.
27. Borzychowski AM, Sargent IL, Redman CW. Inflammation and pre-eclampsia. Semin Fetal Neonatal Med 2006; 11:309-16.
28. Palmer G, Lipsky BP, Smithgall MD et al. The IL-1 receptor accessory protein (AcP) is required for IL-33 signaling and soluble AcP enhances the ability of soluble ST2 to inhibit IL-33. Cytokine 2008; 42:358-64.
29. Okamura H, Tsutsi H, Komatsu T et al. Cloning of a new cytokine that induces IFN-gamma production by T cells. Nature 1995; 378:88-91.
30. Nakanishi K, Yoshimoto T, Tsutsui H, Okamura H. Interleukin-18 regulates both Th1 and Th2 responses. Annu Rev Immunol 2001; 19:423-74.
31. Huang X, Huang H, Dong M, Yao Q, Wang H. Serum and placental interleukin-18 are elevated in preeclampsia. J Reprod Immunol 2005; 65:77-87.
32. Novick D, Kim SH, Fantuzzi G, Reznikov LL, Dinarello CA, Rubinstein M. Interleukin-18 binding protein: a novel modulator of the Th1 cytokine response. Immunity 1999; 10:127-36.
33. Nold MF, Nold-Petry CA, Zepp JA, Palmer BE, Bufler P, Dinarello CA. IL-37 is a fundamental inhibitor of innate immunity. Nat Immunol 2010; 11:1014-22.
34. Kumar S, Hanning CR, Brigham-Burke MR et al. Interleukin-1F7B (IL-1H4/IL-1F7) is processed by caspase-1 and mature IL-1F7B binds to the IL-18 receptor but does not induce IFN-gamma production. Cytokine 2002; 18:61-71.
35. Pan G, Risser P, Mao W et al. IL-1H, an interleukin 1-related protein that binds IL-18 receptor/IL-1Rrp. Cytokine 2001; 13:1-7.
36. Bufler P, Azam T, Gamboni-Robertson F et al. A complex of the IL-1 homologue IL-1F7b and IL-18-binding protein reduces IL-18 activity. Proc Natl Acad Sci USA 2002; 99:13723-8.
37. Sharma S, Kulk N, Nold MF et al. The IL-1 family member 7b translocates to the nucleus and down-regulates proinflammatory cytokines. J Immunol 2008; 180:5477-82.
38. van de Veerdonk FL, Stoeckman AK, Wu G et al. IL-38 binds to the IL-36 receptor and has biological effects on immune cells similar to IL-36 receptor antagonist. Proc Natl Acad Sci USA 2012; 109:3001-5.
39. Towne JE, Garka KE, Renshaw BR, Virca GD, Sims JE. Interleukin (IL)-1F6, IL-1F8, and IL-1F9 signal through IL-1Rrp2 and IL-1RAcP to activate the pathway leading to NF-kappaB and MAPKs. J Biol Chem 2004; 279:13677-88.
40. Redman CW, Tannetta DS, Dragovic RA et al. Review: Does size matter? Placental debris and the pathophysiology of pre-eclampsia. Placenta 2012; 33(Suppl):S48-54.
41. Southcombe J, Tannetta D, Redman C, Sargent I. The immunomodulatory role of syncytiotrophoblast microvesicles. PLOS ONE 2011; 6:e20245.
42. Barton JL, Herbst R, Bosisio D, Higgins L, Nicklin MJ. A tissue specific IL-1 receptor antagonist homolog from the IL-1 cluster lacks IL-1, IL-1ra, IL-18 and IL-18 antagonist activities. Eur J Immunol 2000; 30:3299-308.
43. Kumar S, McDonnell PC, Lehr R et al. Identification and initial characterization of four novel members of the interleukin-1 family. J Biol Chem 2000; 275:10308-14.
44. Busfield SJ, Comrack CA, Yu G et al. Identification and gene organization of three novel members of the IL-1 family on human chromosome 2. Genomics 2000; 66:213-6.
45. Mulero JJ, Pace AM, Nelken ST et al. IL1HY1: A novel interleukin-1 receptor antagonist gene. Biochem Biophys Res Commun 1999; 263:702-6.
46. Towne JE, Sims JE. IL-36 in psoriasis. Curr Opin Pharmacol 2012; 12:486-90.
47. Smith DE, Renshaw BR, Ketchem RR, Kubin M, Garka KE, Sims JE. Four new members expand the interleukin-1 superfamily. J Biol Chem 2000; 275:1169-75.
48. Ichii O, Otsuka S, Sasaki N et al. Local overexpression of interleukin-1 family, member 6 relates to the development of tubulointerstitial lesions. Lab Invest 2010; 90:459-75.
49. Debets R, Timans JC, Homey B et al. Two novel IL-1 family members, IL-1 delta and IL-1 epsilon, function as an antagonist and agonist of NF-kappa B activation through the orphan IL-1 receptor-related protein 2. J Immunol 2001; 167:1440-6.
50. Vigne S, Palmer G, Martin P et al. IL-36 signaling amplifies Th1 responses by enhancing proliferation and Th1 polarization of naive CD4+ T cells. Blood 2012; 120:3478-87.
51. Vigne S, Palmer G, Lamacchia C et al. IL-36R ligands are potent regulators of dendritic and T cells. Blood 2011; 118:5813-23.
52. Onoufriadis A, Simpson MA, Pink AE et al. Mutations in IL36RN/IL1F5 are associated with the severe episodic inflammatory skin disease known as generalized pustular psoriasis. Am J Hum Genet 2011; 89:432-7. [CrossRef]
53. Marrakchi S, Guigue P, Renshaw BR et al. Interleukin-36-receptor antagonist deficiency and generalized pustular psoriasis. N Engl J Med 2011; 365:620-8.
54. Imaeda H, Takahashi K, Fujimoto T et al. Epithelial expression of interleukin-37b in inflammatory bowel disease. Clin Exp Immunol 2013; 172:410-6.
55. Taylor SL, Renshaw BR, Garka KE, Smith DE, Sims JE. Genomic organization of the interleukin-1 locus. Genomics 2002; 79:726-33.
56. Li C, Ji H, Cai Y et al. Serum interleukin-37 concentrations and HBeAg seroconversion in chronic HBV patients during telbivudine treatment. J Interferon Cytokine Res 2013; 33:612-8.
57. Bulau AM, Fink M, Maucksch C et al. In vivo expression of interleukin-37 reduces local and systemic inflammation in concanavalin A-induced hepatitis. ScientificWorldJournal 2011; 11:2480-90.
58. Wanderer AA. Ischemic-reperfusion syndromes: biochemical and immunologic rationale for IL-1 targeted therapy. Clin Immunol 2008; 128:127-32.
59. Sakai N, Van Sweringen HL, Belizaire RM et al. Interleukin-37 reduces liver inflammatory injury via effects on hepatocytes and non-parenchymal cells. J Gastroenterol Hepatol 2012; 27:1609-16.
60. Wu B, Meng K, Ji Q et al. Interleukin-37 ameliorates myocardial ischaemia/reperfusion injury in mice. Clin Exp Immunol 2014; 176:438-51.